| Literature DB >> 35625980 |
Simone Perna1, Hajar Alawadhi1, Antonella Riva2, Pietro Allegrini2, Giovanna Petrangolini2, Clara Gasparri3, Tariq A Alalwan1, Mariangela Rondanelli4,5.
Abstract
BACKGROUND: Cancer is an irregular proliferation of cells that starts with a gene mutation that alters cellular function, is triggered by several factors, and can be inherited or acquired. The aim of this review is to discuss the anticancer activity of basil and its components' strength, focusing on its implication in cancer prevention and treatment.Entities:
Keywords: anticancer; antioxidant activity; apoptosis; basil extract
Year: 2022 PMID: 35625980 PMCID: PMC9139360 DOI: 10.3390/cancers14102375
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.575
Anticarcinogenic effects of basil extracts in animal studies.
| Paper | Type of Study and Level of Evidence | Compound/Extract | Sample | Posology/Treatment | Main Results |
|---|---|---|---|---|---|
| Nangia-Makker et al. [ | Animal study | MCF10ADCIS.com cells injected in female nude mice | 4 mg/mL lyophilized | Slowed down MCF10ADCIS.com tumor growth and progression | |
| Taie et al. [ | Animal study | Ehrlich ascites carcinoma cell line injected in female Swiss albino mice 22–25 g; 8–10 weeks old | Ethanolic extracts with | ||
| Mahmoud [ | Animal study | Ehrlich ascites carcinoma cell line (EACC) injected in 48 female Swiss albino mice weighting 20–25 g; 7–8 weeks old | Several volumes of marigold and basil essential oils to finalize with 25, 50, 75, 100, and 200 µg/mL concentrations | Essential oils significantly prevented tumor development (i.e., decreased total EACC number and increased the percentage of dead cells). The pre-initiation treatment was most effective compared to the initiation and post-initiation treatments, with marigold being more effective (i.e., higher percentage of dead cells) |
Anticarcinogenic effects of basil extracts in laboratory in vitro studies.
| Paper | Type of Study and Level of Evidence | Compound/Extract | Sample | Posology/Treatment | Main Results |
|---|---|---|---|---|---|
| Gajendiran et al. [ | Laboratory study | Human osteosarcoma cell line (MG63) | Increased cell line deterioration and death with the increase in concentration of | ||
| Alkhateeb et al. [ | Laboratory study | Human MCF7 breast cancer cell line | Greater anticancer and antioxidant activities of | ||
| Aburjai et al. [ | Laboratory study | Three different cancer cell lines: MDA–MB–231 (triple-negative breast cancer cell line), MCF7 (breast cancer), and U–87 MG (glioblastoma) | Weight by weight ( | The | |
| Indrayudha and Hapsari [ | Laboratory study | Combination of | T47D cancer cells | Combined | |
| Doguer et al. [ | Laboratory study | Purple basil (PB) dried leaves’ aqueous extract added to sirkencubin syrup (SC) | Human colon carcinoma cells (Caco-2) | Various concentrations (15–40 µL) of purple basil sirkencubin) in 100 µL of fresh medium (total of 150–400 μL/mL) | Half-maximal inhibitory concentration (IC50) values of SC and PBS were 288.1 and 239.8, respectively. PBS showed better results in terms of anticancer activity against (Caco-2). |
| Manikandan et al. [ | Laboratory study | A549 lung cancer cells | Mixture of 5 g of leaf powder and 50 mL of sterile distilled water; 2 mL of the mixture treated with 100 mL of 1 mM AgNO3 solution | AgNPs fabricated with | |
| Elansary & Mahmoud [ | Laboratory study | Line HeLa, MCF–7, Jurkat, HT–29, T24, MIA PaCa-2 cancer cells and one normal human cell line HEK–293 | Different concentrations of the six international basil cultivars | Compounds present in | |
| Mahmoud [ | Laboratory study | Human promyelocytic leukemia cell lines (HL–60 and NB4) and experimental animal model cancer cells (Ehrlich ascites carcinoma cells, EACC). | Several volumes of marigold and basil essential oils finalized to 25, 50, 75, 100, and 200 µg/mL concentrations | Dead cells increased with increasing concentrations of both estragole and marigold. | |
| Hanachi et al. [ | Laboratory study | Human gastric adenocarcinoma (AGS) and human ovarian carcinoma (SKOV–3) cancer cell lines | 0.5 mg/mL to 5 mg/mL concentrations | Toxicity of | |
| Sharma et al. [ | Laboratory study | Extraction of | Human liver cancer cell line HepG2 | 100 μg/mL (202.389 μM) concentration for 96 h | Cell death was only 41%, thereby indicating its ineffectiveness (in purified form) as an anticarcinogenic agent, with low cytotoxicity activity on the HepG2 liver cancer cell line. |
| Zarlaha et al. [ | Laboratory study | Human cervix adenocarcinoma HeLa cells, human melanoma FemX cells, human chronic myelogenous leukemia K562 cells, and human ovarian SKOV3 cells | Ranging from 12.5 to 200 μg/mL for 72 h (200, 100, 50, 25, and 12.5 μM) | The phytochemicals rosmarinic and caffeic acids, along with the essential oils eugenol, isoeugenol, and linalool, showed significant anticancer activity on the four cell lines—especially the SKOV3 cell line. | |
| Abbasi et al. [ | Laboratory study | HepG2 liver carcinoma cells | AgNO3 (1 mM) was added to BC (15 g callus) and AE (anthocyanin) extracts at different ratios (1:1, 1:2, 1:5, and 1:10) | AE–AgNPs showed significant anticancer activity against the HepG2 cell line (75% mortality at 200 µg/mL) compared to BC–AgNPs (approximately 27% mortality at 200 µg/mL). | |
| Złotek et al. [ | Laboratory study | Human squamous carcinoma cell line SCC–15 (ATCC CRL1623) | Different concentrations of the extract (0.125, 0.250, 0.500, and 1.000 mg/mL) | Elicitation of basil with arachidonic acid induced overproduction of phenolic compounds that resulted in a dose-dependent decline in cell metabolism, with greater anticancer activity at higher concentrations. | |
| Alanazi [ | Laboratory study | Human lung carcinoma cell line (A549), human prostate cancer cell line (PC3), and cervical cancer cell line (HeLa) | Basil extract concentrations (333, 166.5, and 83.3 mg/mL) for A549 and PC-3 cells, and lower concentrations (41.6, 20.8, and 10.4 mg/mL) for HeLa cells. | Basil extract worked significantly against HeLa cells, but less so against PC–3 cells. Achillea extract worked significantly against the PC–3 cell line. |
Immunomodulatory effects of tulsi basil (Ocimum tenuiflorum) extracts in the laboratory in human clinical trials.
| Paper | Type of Study and Level of Evidence | Compound/Extract | Sample | Posology/Treatment | Main Results |
|---|---|---|---|---|---|
| Prasad [ | Randomized, placebo-controlled clinical trial | Healthy adults (30) aged 18–30 years | 1000 mg/day for 2 weeks | Increased physical activity, while lowering increments of lactic acid. Decreased fatigue and CK levels. | |
| Mondal et al. [ | Randomized, double-blind, placebo-controlled crossover | Healthy adults (22) aged 22–37 years | 300 mg/day for 4 weeks | Increase in cytokine levels, especially (interferon- | |
| Sharma [ | Open clinical trial | Adults with asthma (20) | 500 mg × 3/day for a week | ||
| Rajalakshmi et al. [ | Clinical trial (level 1) | Adults with viral hepatitis (20) aged 10–60 years | 10 g/day, for 2–3 weeks, depending on the severity of the case | Enhancement of all symptoms within 2 weeks. | |
| Das et al. [ | Randomized, parallel-controlled clinical trial (level 1) | Adults with viral encephalitis (14) | 2.5 g × 4/day for 4 weeks | In comparison with steroids, the survival rate was boosted when the examined extract was applied. |
Figure 1Main mechanisms and effects of Ocimum (basil) in immunomodulation and inflammation response.